Your browser doesn't support javascript.
ABSTRACT
Immune-mediated inflammatory diseases (IMIDs) of the joints, gut and skin are treated with inhibitors of inflammatory cytokines. These cytokines are involved in the pathogenesis of coronavirus disease 2019 (COVID-19). Investigating anti-SARS-CoV-2 antibody responses in IMIDs we observed a significantly reduced incidence of SARS-CoV-2 infection in IMID patients treated with cytokine inhibitors compared to patients receiving no such inhibitors and two healthy control populations, despite similar social exposure. Hence, cytokine inhibitors seem to at least partially protect from SARS-CoV-2 infection.Authors David Simon and Koray Tascilar contributed equally to this work. Authors Markus F. Neurath and Georg Schett share senior authorship.

Full text: Available Collection: Preprints Database: EuropePMC Type of study: Prevalence study / Risk factors Language: English Year: 2020 Document Type: Preprint

Full text: Available Collection: Preprints Database: EuropePMC Type of study: Prevalence study / Risk factors Language: English Year: 2020 Document Type: Preprint